Yves Dutronc

Yves Dutronc

Auto-generated profile, based on publicly available information

Yves Dutronc

Eli Lilly and Company, Indianapolis, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
KWK.W. Wyrwich
K.W. Wyrwich
HKH. Kitchen
H. Kitchen
SKS. Knight
S. Knight
NANatalie Valerie Jane Aldhouse
Natalie Valerie Jane Aldhouse
JMJ. Macey
J. Macey
BKB.A. King
B.A. King
Background Content valid and clinically meaningful instruments are required to evaluate outcomes of therapeutic interventions in alopecia areata (AA). Objective To develop an investigator global assessment (IGA) to interpret treatment response in AA treatment studies. Methods Qualitative interviews were conducted in the US with expert dermatologists and AA patients who had experienced ≥50% scalp hair loss. Thematic data analysis identified critical outcomes and evaluated the content validity of the new IGA. Results Expert clinicians (n=10) judged AA treatment success by the amount of scalp hair growth (median 80% scalp hair). Adult (n=25) and adolescent (n=5) patients participated. Scalp hair loss was the most bothersome AA sign/symptom to most patients. Perceived treatment success ‐‐ short of 100% scalp hair ‐‐ was the presence of ~70‐90% scalp hair (median 80%). Using additional clinician and patient insights, the AA‐IGA™ was developed as an ordinal, static measure comprising five severity categories of the Severity of Alopecia Tool (SALT) 0‐100% scores. Nearly all queried clinicians and patients in this study agreed that for patients with ≥ 50% scalp hair loss, successful treatment would be hair regrowth resulting in ≤ 20% scalp hair loss, and supported the AA‐IGA™ as a meaningful clinician‐reported measure for this patient population. Conclusions We recommend the use of the SALT to assess the extent (0‐100%) of scalp hair loss. Using the SALT assessment, the AA‐IGA™ is a robust ordinal measure providing distinct and clinically meaningful gradations of scalp hair loss that reflects patients’ and expert clinicians’ perspectives and treatment expectations.

11 September 2020 in Journal of Patient-Reported Outcomes
Verified
Journal Article
Open access
PDF file
NANatalie Valerie Jane Aldhouse
Natalie Valerie Jane Aldhouse
HKHelen Kitchen
Helen Kitchen
SKSarah Knight
Sarah Knight
JMJake Macey
Jake Macey
FNFabio P. Nunes
Fabio P. Nunes
KWKathleen W. Wyrwich
Kathleen W. Wyrwich
Background: Alopecia areata (AA) is characterized by hair loss that can affect the scalp and body. This study describes the psychosocial burden of AA. Methods: Participants diagnosed with AA who had experienced ≥50% scalp hair loss according to the Severity of Alopecia Tool (SALT) were identified by clinicians. A semi-structured interview guide, developed with expert clinician input, included open-ended questions to explore patients’ experiences of living with AA. Data were thematically analyzed to identify concepts and relationships. Results: Participants (n = 45, 58% female, mean age 33.3 years [range 15–72], mean SALT 67.2 [range 0–100]) described the AA diagnosis as “devastating”. Both males and females reported emotional and psychological impacts of AA including feeling sad/depressed (n = 21), embarrassed/ashamed (n = 10) and angry/frustrated (n = 3). Patients felt helpless (n = 5) due to the unpredictability of disease recurrence, and anxious (n = 19) about judgement from others. Many patients avoided social situations (n = 18), which impaired relationships and increased isolation. Coping strategies included concealment of hair loss through wigs or make-up, although fear of the displacement of these coverings also caused anxiety and the avoidance of activities that could result in scalp exposure (n = 22). Some patients became more accepting of AA over time, which lessened the emotional impact, though efficacious treatment was still desired. A conceptual framework was developed, and a conceptual model was created to depict the relationship between the physical signs/symptoms and the associated psychosocial effects of AA. Conclusion: AA impairs patients’ emotional and psychological wellbeing, relationships and lifestyles. Greater disease awareness and effective treatments are needed.

17 August 2020 in American Journal of Clinical Dermatology
Verified
Journal Article
Open access
PDF file
KWKathleen W. Wyrwich
Kathleen W. Wyrwich
HKHelen Kitchen
Helen Kitchen
SKSarah Knight
Sarah Knight
NANatalie Valerie Jane Aldhouse
Natalie Valerie Jane Aldhouse
JMJake Macey
Jake Macey
BKBrett A. King
Brett A. King
Background Eyebrow and eyelash hair loss and nail damage—in addition to scalp hair loss—are important signs/symptoms of alopecia areata (AA) to patients and deserve assessment in AA clinical trials. Objectives Our objective was to develop clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures and accompanying photoguides to aid in the assessment of AA-related eyebrow, eyelash and nail signs/symptoms. Methods Iterative rounds of qualitative, semi-structured interviews were conducted with US expert dermatologists and North American patients with AA. Patients with eyebrow, eyelash and nail involvement were purposefully sampled. Interview transcripts were qualitatively analyzed. Results Dermatologists (n = 10) described eyebrow and eyelash loss as concerning for affected patients and, along with nail appearance, as deserving assessment. Dermatologist data informed the development of single item, 4-point Likert-type ClinRO and PRO measures of current eyebrow loss, eyelash loss and nail appearance and a PRO measure of eye irritation. Patients (n = 45, age 15–72 years) confirmed the importance and relevance of these signs/symptoms. Interim revision resulted in measures that were understood by and relevant to patients. Dermatologists (n = 5) and patients (n = 10, age 21–54 years) participated in the development of the eyebrow, eyelash and nail photoguides and confirmed that they included photos that appropriately represented different severity levels and were helpful to derive and standardize ratings across raters. Conclusions The ClinRO and PRO measures for eyebrow, eyelash and nail appearance, with their accompanying photoguides and the PRO Measure for Eye Irritation provide clear and meaningful assessments of outcomes important to patients with AA.

14 September 2023 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
BKBrett King
Brett King
JSJerry Shapiro
Jerry Shapiro
MOManabu Ohyama
Manabu Ohyama
AEAlexander Egeberg
Alexander Egeberg
Bianca Maria PiracciniBianca Maria Piraccini
Bianca Maria Piraccini
YDYves Dutronc
Yves Dutronc
Baricitinib is approved for the treatment of adults with severe alopecia areata (AA). In the absence of robust data on the patterns of regrowth during treatment of severe AA, there is a gap in the knowledge regarding treatment expectations. To examine whether different clinical response subgroups could be identified in baricitinib-treated patients with severe AA and factors that contribute to these subgroups. The BRAVE-AA1 and BRAVE-AA2 phase III trials enrolled patients with severe AA [Severity of Alopecia Tool (SALT) score ≥ 50 (≥ 50% scalp hair loss)]. Patients randomized to baricitinib 4 mg or 2 mg retained their treatment allocation for 52 weeks. Based on patterns identified through growth mixture modelling (GMM), patients were categorized into responder subgroups according to when they first achieved ≥ 30% improvement from baseline in SALT score (SALT30). For each responder subgroup, trajectories of response (i.e. achievement of a SALT score ≤ 20, SALT score ≤ 10 and ≥ 50% change from baseline in SALT score) and baseline disease characteristics are reported. Respectively, 515 and 340 patients were randomized to once-daily baricitinib 4 mg and 2 mg at baseline; 69% and 51%, respectively, achieved SALT30 at least once by week 52. Based on GMM findings, we identified three responder subgroups: early (SALT30 by week 12), gradual (SALT30 after week 12–week 36) and late (SALT30 after week 36–week 52). The proportions of early, gradual and late responders and nonresponders were, respectively, 33%, 28%, 8% and 31% among patients treated with baricitinib 4 mg, and 20%, 23%, 9% and 49%, respectively, among those treated with baricitinib 2 mg. Early responders had a shorter trajectory to maximal clinical outcomes (e.g. > 78% achieved a SALT score ≤ 20 by week 36) vs. gradual or late responders. Early responders were more frequent among patients with baseline severe AA (SALT score 50 to < 95) vs. very severe AA (SALT score 95–100). Overall, responders (early to late) were more frequent in patients with short (< 4 years) episodes of hair loss. These analyses identified early, gradual and late responder subgroups for scalp hair regrowth in baricitinib-treated patients with severe AA, and that these subgroups are influenced by baseline characteristics. Findings from these analyses will help to inform treatment expectations for scalp hair regrowth.

12 March 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
KWK.W. Wyrwich
K.W. Wyrwich
HKH. Kitchen
H. Kitchen
SKS. Knight
S. Knight
NANatalie Valerie Jane Aldhouse
Natalie Valerie Jane Aldhouse
JMJ. Macey
J. Macey
BKB.A. King
B.A. King
Background Valid patient‐reported outcome (PRO) measures are required to evaluate alopecia areata (AA) treatments. Objectives To develop a content‐valid and clinically meaningful PRO measure to assess AA scalp hair loss with scores comparable to the 5‐response level AA Investigator Global Assessment (AA‐IGA™). Methods A draft PRO measure was developed based on input from 10 AA clinical experts. The PRO measure was cognitively debriefed, modified, and finalized through two rounds of qualitative semi‐structured interviews with patients with AA who had experienced ≥50% scalp hair loss. Data were thematically analysed. Results Adults (Round 1: n=25; Round 2: n=15) and adolescents aged 15–17 (Round 1: n=5) in North America participated. All patients named scalp hair loss as a key AA sign/symptom. Patients demonstrated the ability to self‐report their current amount of scalp hair using percentages. In Round 1 not all patients interpreted the measurement concept consistently; therefore, the PRO was modified to clarify the measurement concept to improve usability. Following modifications, Round 2 patients responded without difficulty to the PRO measure. Patients confirmed that they could use the 5‐level response scale to rate their scalp hair loss (No missing hair, 0%; Limited, 1–20%; Moderate, 21–49%; Large, 50–94%; Nearly all or all, 95–100%). Almost all patients deemed hair regrowth resulting in ≤20% scalp hair loss a treatment success. Conclusions The Scalp Hair Assessment PRO™ is a content‐valid, clinically meaningful assessment of distinct gradations of scalp hair loss for evaluating AA treatment for patients with ≥50% hair loss at baseline.

1 November 2020 in Journal of Investigative Dermatology Symposium Proceedings
Verified
Journal Article
Closed access
KWKathleen W. Wyrwich
Kathleen W. Wyrwich
HKHelen Kitchen
Helen Kitchen
SKSarah Knight
Sarah Knight
NANatalie Valerie Jane Aldhouse
Natalie Valerie Jane Aldhouse
JMJake Macey
Jake Macey
BKBrett A. King
Brett A. King